• Comprehensive menu in inflammatory diseases and oncology
  • Validated on principle drug and biosimilars
  • Ready to use reagents
  • Standardised protocols from sample collection to result interpretation
  • Automation ready – validated on several open platform ELISA systems

LISA-TRACKER anti-Secukinumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of anti-Secukinumab antibodies in human serum.

Secukinumab is indicated in the treatment of moderate to severe plaque psoriasis, of active psoriatic arthritis and active ankylosing spondylitis. Secukinumab is a human IgG1k monoclonal antibody directed against the human lL-17A cytokine.  IL-17A is a natural pro-inflammatory cytokine which is involved in normal inflammatory and immune responses.  It plays a regulatory role in the pathogenesis of the diseases defined above. During the treatment, some patients can develop antibodies against Secukinumab.

  • Baeten D et al. Secukinumab, interleukin-17A inhibition in ankylosing spondylitis.  N Engl J Med, 2015; 373: 2534-48.
  • Bagel J et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-bind, placebo-controlled phase 3b study.  J Am Acad Dermatol, 2017; 77; 667-74.
  • Baraliakos X et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clinical and Experimental Rheumatology, 2017.
  • Blauvelt A et al. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than Ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.  JEADV, 2017, 31, 1693-1699.
  • Bruin G et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis.  The Journal of Clinical Pharmacology, 2017, 57(7), 876-885.
  • Frieder J et al. Secukinumab: a review of the anti-IL-17-A biologic for the treatment of psoriasis.  Ther Adv Chronic Dis, 2018, Vol.9 (1) 5-21.
  • Gaffen L et al. An overview of IL-17 function and signaling, Cytokine, 2008; 43(3); 402-407.
  • Gaffen L et al. Structure and signaling in the IL-17 receptor superfamily.  Nat Rev Immunol, 2009; 9(8):556.
  • Hueber W and al. Effects of AIN457, a fully human antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis.  Sci Transl Med, 2010, Vol 2 Issue 52.
  • Kirkham BW et al. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.  Immunology, 2013, 141, 133-142.
  • Koenders MI et al. Secukinumab for rheumatology: development and its potential place in therapy.  Drug Design, Development and Therapy, 2016:10, 2069-2080.
  • Langley RG and al. Secukinumab in plaque Psoriasis – Results of two phase 3 trials.  N Engl J Med, 2014, 371;4.
  • Mease PJ and al. Secukinumab inhibition of Interleukin-17A in patients with psoriatic arthritis.  N Engl J Med, 2015, 373(14):1329-39.
  • Onishi RM et al. Interleukin-17 and its target genes: mechanism of interleukin-17 function in disease. Immunology, 2010, 129, 311-321.
  • Pavelka K et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-bind phase 3 study, MEASURE 3. Arthritis Research & Therapy, 2017, 19:285.

LISA-TRACKER Duo Secukinumab

LISA-TRACKER Secukinumab

ImmunoTROL LISA-TRACKER Secukinumab

ImmunoTROL LISA-TRACKER anti-Secukinumab